Allogene Therapeutics Stock Intrinsic Value – Allogene Therapeutics Reorganizes Pipeline Plans

🌥️Trending News

Allogene Therapeutics ($NASDAQ:ALLO) is a clinical-stage biotechnology company that specializes in the development of allogeneic CAR T cell therapies for the treatment of cancer. They have been working on reorganizing their pipeline of CAR T therapies, however, they have recently made the decision to abandon those plans. This decision comes after a comprehensive review of the company’s pipeline plans and the near-term opportunities. The company has explained that in light of the recent advancements in their CAR T technology, as well as an improved understanding of the biology and efficacy of their product candidates, they have concluded that the reorganization of their pipeline is not necessary at this time.

Allogene plans to use the resources and capabilities from their CAR T program to further develop and expand their pipeline. Allogene is dedicated to developing innovative allogeneic cell therapies to treat cancer and has been making great strides towards achieving this goal. They are committed to continuing to work on expanding their pipeline of therapies and hope to bring more hope and better treatments to patients around the world.

Stock Price

On Friday, Allogene Therapeutics announced a reorganization of their pipeline plans in response to the current market conditions. This change caused their stock to open at $2.8 and close at $2.9, a 14.0% plunge from the previous closing price of $3.4. The company stated that the new plans will focus on advancing their lead programs in both clinical-stage and preclinical-stage, as well as utilizing their existing resources to further develop their pipeline.

In order to achieve this, they will reduce spending in their early research and development efforts, while still continuing to identify high-value opportunities in the market. The stock market reacted accordingly, and the company is currently reassessing its strategy in light of these changes. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Allogene Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Allogene Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Allogene Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Allogene Therapeutics are shown below. More…

Analysis – Allogene Therapeutics Stock Intrinsic Value

At GoodWhale, we performed a thorough analysis of ALLOGENE THERAPEUTICS‘s wellbeing. Based on our proprietary Valuation Line, the fair value of ALLOGENE THERAPEUTICS’ share is approximately $3.8. However, presently ALLOGENE THERAPEUTICS’ stock is traded at $2.9, which means that it is currently undervalued by 23.6%. This presents an excellent opportunity for investors to buy into ALLOGENE THERAPEUTICS’ stock, as the price is expected to rise in the near future. More…

Peers

Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.

– Arvinas Inc ($NASDAQ:ARVN)

Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.

– Nascent Biotech Inc ($OTCPK:NBIO)

Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.

– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)

JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.

Summary

Allogene Therapeutics is a biotechnology company focused on developing next-generation cell therapies for cancer. Recently, the company announced plans to reorganize its pipeline and move projects from early development to clinical trails. This news caused the stock price to drop the same day, leaving investors uncertain about the future prospects of the company.

Additionally, investors should keep an eye on other companies in the same field as well as the broader biotech industry, as this element could affect Allogene’s success. Ultimately, investors must decide if Allogene is worth the risk relative to other potential investments.